Vident Investment Advisory LLC reduced its position in USANA Health Sciences, Inc. (NYSE:USNA) by 3.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 8,705 shares of the company’s stock after selling 267 shares during the period. Vident Investment Advisory LLC’s holdings in USANA Health Sciences were worth $892,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd purchased a new stake in USANA Health Sciences in the 1st quarter worth approximately $29,000. Altshuler Shaham Ltd acquired a new position in shares of USANA Health Sciences in the 1st quarter valued at $37,000. Federated Hermes Inc. boosted its holdings in shares of USANA Health Sciences by 329.7% in the 1st quarter. Federated Hermes Inc. now owns 593 shares of the company’s stock valued at $58,000 after purchasing an additional 455 shares during the last quarter. Captrust Financial Advisors boosted its holdings in shares of USANA Health Sciences by 3,400.0% in the 1st quarter. Captrust Financial Advisors now owns 700 shares of the company’s stock valued at $68,000 after purchasing an additional 680 shares during the last quarter. Finally, Intersect Capital LLC acquired a new position in shares of USANA Health Sciences in the 2nd quarter valued at $200,000. 54.77% of the stock is owned by hedge funds and other institutional investors.
In other USANA Health Sciences news, Director Frederic J. Winssinger sold 926 shares of the business’s stock in a transaction on Thursday, July 29th. The shares were sold at an average price of $99.08, for a total value of $91,748.08. Following the transaction, the director now owns 2,516 shares in the company, valued at approximately $249,285.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John Turman Fleming sold 300 shares of the business’s stock in a transaction on Monday, August 30th. The stock was sold at an average price of $97.26, for a total transaction of $29,178.00. Following the completion of the transaction, the director now owns 851 shares in the company, valued at approximately $82,768.26. The disclosure for this sale can be found here. Insiders have sold a total of 3,435 shares of company stock worth $331,837 in the last 90 days. Company insiders own 0.21% of the company’s stock.
USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, July 27th. The company reported $1.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.78 by $0.09. The business had revenue of $336.84 million for the quarter, compared to analyst estimates of $340.20 million. USANA Health Sciences had a net margin of 11.09% and a return on equity of 33.65%. Equities research analysts forecast that USANA Health Sciences, Inc. will post 6.31 EPS for the current year.
A number of brokerages have weighed in on USNA. Tigress Financial reiterated a “buy” rating and issued a $122.00 price target on shares of USANA Health Sciences in a report on Friday, October 8th. Zacks Investment Research upgraded shares of USANA Health Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, September 29th.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, Personal Care and Skincare, and All Other. The Essentials Nutritionals category includes vitamin and mineral supplements that provide a foundation of advanced total body nutrition for every age group.
See Also: Investing in Growth Stocks
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.